JP2022519696A - Ｔｙｋ２偽キナーゼリガンド - Google Patents

Ｔｙｋ２偽キナーゼリガンド Download PDF

Info

Publication number
JP2022519696A
JP2022519696A JP2021546005A JP2021546005A JP2022519696A JP 2022519696 A JP2022519696 A JP 2022519696A JP 2021546005 A JP2021546005 A JP 2021546005A JP 2021546005 A JP2021546005 A JP 2021546005A JP 2022519696 A JP2022519696 A JP 2022519696A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
solvate
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021546005A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022519696A5 (https=
JPWO2020163778A5 (https=
Inventor
モハン，ラジュ
ナス，ジョン
ハリス，ジェイソン
ユアン，シェンドン
Original Assignee
ベンティックス バイオサイエンシーズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベンティックス バイオサイエンシーズ，インク． filed Critical ベンティックス バイオサイエンシーズ，インク．
Publication of JP2022519696A publication Critical patent/JP2022519696A/ja
Publication of JP2022519696A5 publication Critical patent/JP2022519696A5/ja
Publication of JPWO2020163778A5 publication Critical patent/JPWO2020163778A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021546005A 2019-02-07 2020-02-07 Ｔｙｋ２偽キナーゼリガンド Pending JP2022519696A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962802642P 2019-02-07 2019-02-07
US62/802,642 2019-02-07
PCT/US2020/017314 WO2020163778A1 (en) 2019-02-07 2020-02-07 Tyk2 pseudokinase ligands

Publications (3)

Publication Number Publication Date
JP2022519696A true JP2022519696A (ja) 2022-03-24
JP2022519696A5 JP2022519696A5 (https=) 2023-02-15
JPWO2020163778A5 JPWO2020163778A5 (https=) 2023-02-15

Family

ID=71947508

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021546005A Pending JP2022519696A (ja) 2019-02-07 2020-02-07 Ｔｙｋ２偽キナーゼリガンド

Country Status (12)

Country Link
US (1) US20220135567A1 (https=)
EP (1) EP3920931A4 (https=)
JP (1) JP2022519696A (https=)
KR (1) KR20210124409A (https=)
CN (1) CN113677347A (https=)
AU (1) AU2020218267A1 (https=)
BR (1) BR112021015616A2 (https=)
CA (1) CA3129438A1 (https=)
IL (1) IL285429A (https=)
MX (1) MX2021009555A (https=)
SG (1) SG11202108619SA (https=)
WO (1) WO2020163778A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022553841A (ja) * 2019-11-08 2022-12-26 ベンティックス バイオサイエンシーズ，インク． Ｔｙｋ２偽キナーゼリガンド

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019364336B2 (en) 2018-10-22 2023-11-16 Alumis Inc. TYK2 inhibitors and uses thereof
AU2020247990A1 (en) 2019-03-26 2021-11-11 Ventyx Biosciences, Inc. TYK2 pseudokinase ligands
AU2021345181A1 (en) * 2020-09-16 2023-05-04 Alumis Inc Tyk2 inhibitors and uses thereof
CN117043164A (zh) * 2021-01-19 2023-11-10 安锐生物医药科技(广州)有限公司 咪唑并哒嗪或吡唑并嘧啶化合物和组合物
JP2024539280A (ja) 2021-10-25 2024-10-28 カイメラ セラピューティクス， インコーポレイテッド Ｔｙｋ２分解剤およびそれらの使用
WO2025061180A1 (zh) * 2023-09-22 2025-03-27 杭州多域生物技术有限公司 含氮并环类化合物、其药物组合物及其应用
WO2025165746A1 (en) * 2024-01-30 2025-08-07 Ennovathera, Inc. Certain chemical entities, compositions, and methods
WO2025168035A1 (zh) * 2024-02-07 2025-08-14 合肥羿科医药有限公司 杂环类化合物、其药物组合物及其应用
WO2025214467A1 (zh) * 2024-04-12 2025-10-16 江苏恒瑞医药股份有限公司 氨基取代的杂芳环类化合物、其制备方法及其在医药上的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006519226A (ja) * 2003-02-28 2006-08-24 帝人ファーマ株式会社 ピラゾロ［１，５−ａ］ピリミジン誘導体
JP2012507569A (ja) * 2008-10-31 2012-03-29 ジェネンテック， インコーポレイテッド ピラゾロピリミジンｊａｋ阻害剤化合物と方法
JP2019501125A (ja) * 2015-11-18 2019-01-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物
WO2019023468A1 (en) * 2017-07-28 2019-01-31 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201720828A (zh) * 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
JP7160824B2 (ja) * 2017-03-08 2022-10-25 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤、使用およびその製造のための方法
CN110678467B (zh) * 2017-05-22 2023-06-13 豪夫迈·罗氏有限公司 治疗化合物和组合物及其使用方法
JP7179161B2 (ja) * 2018-09-10 2022-11-28 イーライ リリー アンド カンパニー 乾癬および全身性エリテマトーデスの処置に有用なピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミド誘導体
JP7619951B2 (ja) * 2018-10-15 2025-01-22 武田薬品工業株式会社 Ｔｙｋ２阻害剤およびその使用
TWI800696B (zh) * 2018-12-10 2023-05-01 美商美國禮來大藥廠 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物
KR102938141B1 (ko) * 2019-11-08 2026-03-11 벤틱스 바이오사이언스, 인크. Tyk2 슈도키나제 리간드

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006519226A (ja) * 2003-02-28 2006-08-24 帝人ファーマ株式会社 ピラゾロ［１，５−ａ］ピリミジン誘導体
JP2012507569A (ja) * 2008-10-31 2012-03-29 ジェネンテック， インコーポレイテッド ピラゾロピリミジンｊａｋ阻害剤化合物と方法
JP2019501125A (ja) * 2015-11-18 2019-01-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物
WO2019023468A1 (en) * 2017-07-28 2019-01-31 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022553841A (ja) * 2019-11-08 2022-12-26 ベンティックス バイオサイエンシーズ，インク． Ｔｙｋ２偽キナーゼリガンド
JP7635228B2 (ja) 2019-11-08 2025-02-25 ベンティックス バイオサイエンシーズ，インク． Ｔｙｋ２偽キナーゼリガンド

Also Published As

Publication number Publication date
EP3920931A1 (en) 2021-12-15
US20220135567A1 (en) 2022-05-05
SG11202108619SA (en) 2021-09-29
CA3129438A1 (en) 2020-08-13
BR112021015616A2 (pt) 2021-11-09
MX2021009555A (es) 2021-10-13
AU2020218267A1 (en) 2021-09-30
EP3920931A4 (en) 2022-08-10
IL285429A (en) 2021-09-30
CN113677347A (zh) 2021-11-19
KR20210124409A (ko) 2021-10-14
WO2020163778A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
JP2022519696A (ja) Ｔｙｋ２偽キナーゼリガンド
KR102938141B1 (ko) Tyk2 슈도키나제 리간드
JP2022529311A (ja) Ｔｙｋ２偽キナーゼリガンド
JP7617030B2 (ja) Ｊａｋ阻害剤
JP2022549435A (ja) Ｊａｋ阻害剤
JP2022544174A (ja) Ｊａｋ阻害剤
CA3186635A1 (en) Therapeutic agents targeting gpr35
HK40066192B (zh) Tyk2假激酶配体
HK40066192A (zh) Tyk2假激酶配体
HK40080028B (zh) Tyk2假激酶配体
HK40064378A (en) Tyk2 pseudokinase ligands
HK40080028A (en) Tyk2 pseudokinase ligands
HK40080624A (en) Jak inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210831

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20221222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230206

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240813

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241204